Mevacamten, being studied as a possible progenitor of a new family of drugs against hypertrophic obstructive cardiomyopathy (oHcm), compared with placebo has been shown to improve patients’ health conditions at 30 weeks in a new analysis of the phase 3 clinical trial Explorer- Hcm. The results were presented by Bristol Myers Squibb (Bms) at the 70th Annual Congress of the American College of Cardiology (ACC) and published simultaneously in ‘The Lancet’. Mavacamten is a potential first cardiac myosin inhibitor for patients with oHcm, the Usa group reports in a note. At 30 weeks – we read – the change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Kccq Oss) was greater in patients treated with mavacamten than in those treated with placebo, with similar benefits in all Kccq subscales. In addition, compared to placebo, a larger proportion of patients receiving mavacamten achieved a clinically significant (≥20 points) substantial improvement in Kccq Oss: 36% in the mavacamten arm vs 15% in the placebo group. A change of at least 5 points is required to be considered clinically significant. Hypertrophic cardiomyopathy (Hcm) is a chronic progressive disease in which the excessive contraction of the heart muscle and the reduced filling capacity of the left ventricle can cause debilitating symptoms and cardiac dysfunction. In patients, exertion can lead to fatigue or shortness of breath. The disease is also associated with an increased risk of atrial fibrillation, heart attack, heart failure and sudden cardiac death. Cardiomyopathy is estimated to affect one in 500 people, however in many patients it is undiagnosed and / or asymptomatic. “The Kansas City Cardiomyopathy Questionnaire is a disease-specific 23-point questionnaire that quantifies symptoms, physical condition, function and quality of life – explains the study’s principal investigator, John A. Spertus, Clinical Director of Outcomes Research at Saint Luke’s Mid America Heart Institute and Lauer Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City – Using this tool we can demonstrate the significant clinical benefits for patients treated with mavacamten in the study, which decreased at the end of treatment. This new data analysis from the Explorer-Hcm “double-blind placebo-controlled study,” provides important information on the benefits that inhibition of myosin can lead to an improvement in the health status of patients with cardiomyopias severe obstructive hypertrophic thia, an often debilitating chronic disease “.” Mavacamten confirms Bristol Myers Squibb’s continuing dedication to improving the lives of patients, especially those with chronic cardiovascular diseases such as hypertrophic obstructive cardiomyopathy, through scientific discoveries – says Jay Edelberg, head Heart Failure and Cardiomyopathy Development BMS – This new data analysis from the Phase 3 Explorer-Hcm study further supports the scientific evidence indicating the benefit of mavacamten in improving health conditions, symptoms and quality of life of patients with symptomatic hypertrophic obstructive cardiomyopathy. We look forward to offering this new therapy to patients next year. “
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.